• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

    5/22/25 5:30:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email

    MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

    New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest step in the delivery of Sanofi's science-driven, best-in-class workplace portfolio worldwide, notably an expansive corporate hub and R&D center in Cambridge, Massachusetts, which opened in 2022. The New Jersey opening - an investment of $130 million - further strengthens Sanofi's presence in the United States.

    Paul Hudson

    Chief Executive Officer

    "Sanofi is an intrinsic part of the healthcare ecosystem of the United States, where we pioneer advancements in our labs, produce medicines and vaccines that improve people's lives, and grow our talented workforce. Our people are our biggest asset and providing them with a cutting-edge workplace experience is key to help them thrive and do their best work. These flagship offices are designed to inspire creativity, collaboration and innovation — all in service of patients."

    Phil Murphy

    Governor, New Jersey

    "Sanofi's investment in this innovative Morristown facility represents a significant vote of confidence in New Jersey's thriving innovation economy. This facility will drive scientific advancement and economic growth in our state, and its sustainable design and local partnerships will be an asset to the community. We are proud to see Sanofi deepen its commitment to New Jersey as we work together to shape the future of healthcare innovation."

    The new offices bring together nearly 2,000 employees across disciplines in a new 260,000-square-foot facility that features flexible workspaces, digitally enabled smart design, and best-in-class amenities, including wellness rooms, a restaurant open to the public, and the largest outdoor terrace space in New Jersey. Employees enjoy light-filled workspaces that utilize natural materials, largely sourced locally, as well as tactile finishes with contributions from local artists.

    Natalie Bickford

    Executive Vice President, Chief People Officer

    "Morristown exemplifies Sanofi's long-term investment in creating an empowering and purposeful workplace experience. When you walk in the door, you immediately feel that it's a different kind of workplace - digitally enabled, fully accessible and functional, but also beautiful and designed to make people feel connected and inspired. We look forward to welcoming Sanofians and visitors from around the world to our newest site."

    Sanofi's Morristown offices will be US Green Building Council LEED® Gold Certified and compliant with WELL Gold Building standards, incorporating sophisticated design elements that align with Sanofi's commitment to protect people, the planet, and the community. Employees will benefit from sustainable features such as fully subsidized and easily accessible public transportation, including Wi-Fi-enabled shuttles, and electric vehicle chargers on site. The building is designed to use approximately 28% less energy and reduce greenhouse gas emissions by over 24% compared to standard office spaces, while reducing water use by 37% through efficient fixtures and thoughtful design.

    Sanofi helps expand healthcare access in Morristown and beyond in New Jersey

    As part of its commitment to the Morristown community, Sanofi announced a financial contribution to Zufall Health Center, a nonprofit community health center providing affordable, high-quality healthcare for people regardless of income, insurance, or other barriers. The contribution will be used to support core services and team-based care, including updating essential equipment.

    In addition to announcing its support for the Zufall Health Center, Sanofi's Morristown offices will take part in the work of the Meal Recovery Coalition, of which the company is a founding member. Sanofi and other major New Jersey corporations and agencies in the Coalition recover surplus meals from large cafeterias and help to distribute them to food-insecure residents across the state. These partnerships reflect Sanofi's dedication to addressing healthcare disparities and strengthening community resources where its employees live and work.

    To explore career opportunities at Sanofi, please visit https://jobs.sanofi.com/en.

    About Sanofi

    We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

    Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

    Media Relations

    Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]

    Evan Berland | +1 215 432 0234 | [email protected]  

    Timothy Gilbert | +1 516 521 2929 | [email protected]

    Investor Relations

    Thomas Kudsk Larsen |+44 7545 513 693 | [email protected]  

    Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]  

    Felix Lauscher | +1 908 612 7239 | [email protected]  

    Keita Browne | +1 781 249 1766 | [email protected]  

    Nathalie Pham | +33 7 85 93 30 17 | [email protected]  

    Tarik Elgoutni | +1 617 710 3587 | [email protected]  

    Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]  

    Yun Li | +33 6 84 00 90 72 | [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sanofi-opens-new-130-million-nj-offices-in-morristown-showcasing-innovative-modern-design-and-strengthening-us-presence-302462270.html

    SOURCE Sanofi

    Get the next $SNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    2/12/2026Buy → Neutral
    BofA Securities
    1/27/2026Neutral
    Citigroup
    1/16/2026Buy → Neutral
    UBS
    1/6/2026Overweight → Equal Weight
    Barclays
    12/9/2025Buy → Neutral
    Guggenheim
    12/8/2025Overweight → Neutral
    Analyst
    9/8/2025$58.00Equal-Weight → Overweight
    Morgan Stanley
    9/2/2025Hold → Buy
    Deutsche Bank
    More analyst ratings

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi downgraded by BofA Securities

    BofA Securities downgraded Sanofi from Buy to Neutral

    2/12/26 7:23:56 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Sanofi

    Citigroup initiated coverage of Sanofi with a rating of Neutral

    1/27/26 8:49:24 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by UBS

    UBS downgraded Sanofi from Buy to Neutral

    1/16/26 8:32:26 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

    4 - Sanofi (0001121404) (Reporting)

    8/2/21 8:34:24 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Sanofi

    3 - Sanofi (0001121404) (Reporting)

    7/28/21 8:32:04 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    SEC Filings

    View All

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    2/23/26 9:19:13 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Sanofi

    S-8 - Sanofi (0001121404) (Filer)

    2/17/26 1:28:03 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form IRANNOTICE filed by Sanofi

    IRANNOTICE - Sanofi (0001121404) (Filer)

    2/17/26 12:44:21 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezurock® now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)

    Three provinces now cover Rezurock® (belumosudil) through their provincial formularies for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy1A significant step forward for chronic GVHD patients and their families following Health Canada approval (March 2023) and Canada's Drug Agency (CDA-AMC) recommendation in March 2024Chronic GVHD is a serious complication following stem cell transplant, with debilitating symptoms that can last for years2TORONTO, Feb. 3, 2026 /CNW/ - British Columbia and Ontario recently added Rezurock® (belumosudil) to their provincial formularies for adult and pediat

    2/3/26 8:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy

    – New collaboration builds on Sanofi's prior acquisition of DR-0201 and further leverages Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class multispecific antibody therapeutics – – Dren Bio will receive an upfront cash payment of $100 million and is also eligible to receive up to $1.7 billion in future development, regulatory, and commercial milestone payments – – Dren Bio retains the option to co-fund future development in exchange for U.S. co-promotion rights with Sanofi, a 50/50 share of U.S. profits and losses, and milestones plus tiered royalties on ex-U.S. sales – Dren Bio, a privately held, clinical-stage biotechnology company deve

    12/15/25 8:05:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

    6/2/25 1:25:00 AM ET
    $BPMC
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

    5/21/25 7:30:46 PM ET
    $SNY
    $VIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SNY
    Leadership Updates

    Live Leadership Updates

    View All

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ITM Appoints Annette Breunig as Chief People Officer

    Global HR leader to drive ITM's long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief People Officer (CPO). Ms. Breunig brings over 25 years of HR leadership experience at international pharmaceutical, manufacturing and technology companies, including at Siemens AG (FRA: SIE) and Sanofi (NASDAQ:SNY). At ITM, Ms. Breunig will lead the HR team in shaping strategies that unify the organization to achieve both team and business growth objectives while empowering em

    10/13/25 5:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

    TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

    6/9/25 10:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sanofi

    SC 13G/A - Sanofi (0001121404) (Subject)

    11/7/24 2:49:36 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sanofi

    SC 13G - Sanofi (0001121404) (Filed by)

    5/31/24 4:30:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sanofi (Amendment)

    SC 13G/A - Sanofi (0001121404) (Subject)

    2/14/24 3:57:49 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care